The rationale behind this combination strategy relates to the involvement of CXCR4 and its ligand CXCL12 in supporting tumor cell growth and angiogenesis, as well as immunosuppression in the tumor microenvironment [110]. This evidence concerns the gene CXCR4 and neoplasm.